

June 16, 2020

COM-2020-046

Dear provider of healthcare-related services,

As part of our effort to support you and keep you informed regarding rapidly changing measures taken in response to 2019 coronavirus disease (COVID-19), we want to notify you that the Food and Drug Administration (FDA) is warning about a potential drug interaction between remdesivir and chloroquine phosphate (CQ) or hydroxychloroquine sulfate (HQC), where co-administration may result in the reduced antiviral activity of remdesivir.

Remdesivir is an investigational antiviral drug that received an [emergency use authorization \(EUA\)](#) on May 1, 2020, for the treatment of hospitalized COVID-19 patients with severe disease. The safety and efficacy of remdesivir for the treatment of COVID-19 continue to be evaluated.

Additional information is available at the [FDA's Press Announcements](#) portal and in the [fact sheet for health care providers](#).

The situation with the COVID-19 pandemic is dynamic and constantly changing. We strongly encourage the frequent revision of updated information provided by the FDA, the Centers for Disease and Control Prevention (CDC), and the World Health Organization (WHO), to assure that your practices are consistent with the most actualized information.

PharmPix is committed to the health and wellness of our members. It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252, extension 137.

Regards,

Clinical Department

References:

1. Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use. U.S. Food and Drug Administration. (2020). Retrieved June 2020, from https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-warns-newly-discovered-potential-drug-interaction-may-reduce?utm_campaign=061520_PR_FDA%20Warns%20of%20Drug%20Interaction%20With%20Drugs%20Authorized%20to%20Treat%20COVID-19&utm_medium=email&utm_source=Eloqua.
2. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. U.S. Food and Drug Administration. (2020). Retrieved June 2020, from <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment>.

